Menu
VITAL and BARDA are seeking innovations to improve delivery, biodistribution, and durability of long-acting monoclonal antibody and/or nucleic acid-based platforms for PrEP for seasonal and pandemic influenza and other respiratory viruses.
VITAL invites startups and university-backed projects to apply for non-dilutive funding ranging from $50K to $200K. This funding supports the development, evaluation, or validation of innovative solutions aligned with BARDA’s mission to enhance pandemic preparedness and health security.
Are you a startup or university-based project pioneering the future of therapeutics and vaccines? We’re looking for innovative solutions that align with BARDA’s mission to enhance pandemic preparedness and health security. Apply to the VITAL Biotech Accelerator Program and make a global impact!
